Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Outcomes of Induction Chemotherapy in Resectable NSCLC Treated with Radical Surgery: A Pre- and POST-Operative Prognostic Factors Analysis

Chiara Catelli
* ORCID logo ,
Nicola Sarnicola
,
Tommaso Ligabue
,
Piero Paladini
ORCID logo ,
Francesco Bloise
,
Carmelo Bengala
,
Luca Luzzi
Version 1 : Received: 21 September 2023 / Approved: 21 September 2023 / Online: 22 September 2023 (02:57:46 CEST)

How to cite: Catelli, C.; Sarnicola, N.; Ligabue, T.; Paladini, P.; Bloise, F.; Bengala, C.; Luzzi, L. Outcomes of Induction Chemotherapy in Resectable NSCLC Treated with Radical Surgery: A Pre- and POST-Operative Prognostic Factors Analysis. Preprints 2023, 2023091488. https://doi.org/10.20944/preprints202309.1488.v1 Catelli, C.; Sarnicola, N.; Ligabue, T.; Paladini, P.; Bloise, F.; Bengala, C.; Luzzi, L. Outcomes of Induction Chemotherapy in Resectable NSCLC Treated with Radical Surgery: A Pre- and POST-Operative Prognostic Factors Analysis. Preprints 2023, 2023091488. https://doi.org/10.20944/preprints202309.1488.v1

Abstract

The aim of the study is to evaluate the predictive factors of response to induction chemotherapy in patients with resectable NSCLC, treated at the unit of Thoracic Surgery of Siena University Hospital with radical surgery. From January 1, 2013 to December 31, 2020, 78 patients were recruited. We analyzed the outcomes in terms of 5-years OS based on the Estimated Regression Rate, N2 downstaging and age; two patients’ subgroups were created by age (Group A: age <66 years-old; Group B: age >66 years-old). No 5-year OS difference was observed based on age, while it was observed in patients with N2 downstaging (p=0.031). Bewtween patients with N2 downstaging, only patients in Group A had a significantly increased 5-year OS (p=0.019), while this was not observed in Group B (p=0-321); the same result was observed with the Estimated Regression Rate > 50% (Group A p=0.005; Group B p=0.391). The percentage of disease regression and the N2 down-staging after induction chemotherapy have great value on the survival, although this advantage seems to be observed mostly in younger patients. A multidisciplinary oncologic discussion of clinical cases could provide support in the careful selection of the ideal patients to undergo neoadjuvant treatment before radical surgery.

Keywords

NSCLC; neoadjuvant therapy; overall survival; locally advanced; lymph nodal downstaging; induction therapy; thoracic surgery; chemotherapy; resectable; multimodal; age

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.